| Cyclophosphamide and cancer: golden anniversary A Emadi, RJ Jones, RA Brodsky Nature reviews Clinical oncology 6 (11), 638-647, 2009 | 1022 | 2009 |
| Ruthenium-based chemotherapeutics: are they ready for prime time? ES Antonarakis, A Emadi Cancer chemotherapy and pharmacology 66, 1-9, 2010 | 633 | 2010 |
| Arsenic trioxide—an old drug rediscovered A Emadi, SD Gore Blood reviews 24 (4-5), 191-199, 2010 | 331 | 2010 |
| Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review JB Segal, DJ Brotman, AJ Necochea, A Emadi, L Samal, LM Wilson, ... Jama 301 (23), 2472-2485, 2009 | 324 | 2009 |
| Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia GL Uy, I Aldoss, MC Foster, PH Sayre, MJ Wieduwilt, AS Advani, ... Blood, The Journal of the American Society of Hematology 137 (6), 751-762, 2021 | 240 | 2021 |
| Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments J Ding, JE Karp, A Emadi Cancer Biomarkers 19 (4), 353-363, 2017 | 237 | 2017 |
| Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations A Emadi, SA Jun, T Tsukamoto, AT Fathi, MD Minden, CV Dang Experimental hematology 42 (4), 247-251, 2014 | 176 | 2014 |
| Autophagy modulation: a target for cancer treatment development A Duffy, J Le, E Sausville, A Emadi Cancer chemotherapy and pharmacology 75, 439-447, 2015 | 158 | 2015 |
| Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response AT Fathi, H Sadrzadeh, DR Borger, KK Ballen, PC Amrein, EC Attar, ... Blood, The Journal of the American Society of Hematology 120 (23), 4649-4652, 2012 | 132 | 2012 |
| Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia A Emadi, R Faramand, B Carter‐Cooper, S Tolu, LA Ford, RG Lapidus, ... American journal of hematology 90 (5), E77-E79, 2015 | 109 | 2015 |
| Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study A Etemadi, F Kamangar, F Islami, H Poustchi, A Pourshams, P Brennan, ... BMC medicine 13, 1-7, 2015 | 80 | 2015 |
| Vitamin and mineral supplements: do we really need them? F Kamangar, A Emadi International journal of preventive medicine 3 (3), 221, 2012 | 74 | 2012 |
| Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: prospective results from a multi-center study F Rashidi, S Barco, F Kamangar, GA Heresi, A Emadi, C Kaymaz, P Jansa, ... Thrombosis research 198, 135-138, 2021 | 68 | 2021 |
| Intoxication of a hospitalized patient with an isopropanol-based hand sanitizer A Emadi, LA Coberly New England journal of medicine 356 (5), 530-531, 2007 | 68 | 2007 |
| Regiocontrolled synthesis and HIV inhibitory activity of unsymmetrical binaphthoquinone and trimeric naphthoquinone derivatives of conocurvone KW Stagliano, A Emadi, Z Lu, HC Malinakova, B Twenter, M Yu, ... Bioorganic & medicinal chemistry 14 (16), 5651-5665, 2006 | 64 | 2006 |
| Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? E Estey, JE Karp, A Emadi, M Othus, RP Gale Leukemia 34 (3), 671-681, 2020 | 60 | 2020 |
| Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia AT Fathi, SA Wander, R Faramand, A Emadi Seminars in hematology 52 (3), 165-171, 2015 | 60 | 2015 |
| Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy B Bhatnagar, VH Duong, TS Gourdin, ML Tidwell, C Chen, Y Ning, ... Leukemia & lymphoma 55 (7), 1533-1537, 2014 | 60 | 2014 |
| Asparaginase in the treatment of non-ALL hematologic malignancies A Emadi, H Zokaee, EA Sausville Cancer chemotherapy and pharmacology 73, 875-883, 2014 | 55 | 2014 |
| Metabolic inhibitor against tumors having an idh mutation GJ Riggins, MJ Seltzer, T Tsukamoto, C Van Dang, A Emadi US Patent App. 13/697,097, 2013 | 53 | 2013 |
